Article

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

2021-04-28

Abstract excerpt

The global circulation of newly emerging variants of SARS-CoV-2 is a new threat to public health due to their increased transmissibility and immune evasion. Moreover, currently available vaccines and therapeutic antibodies were shown to be less effective against new variants, in particular, the South African (SA) variant, termed 501Y.V2 or B.1.351. To assess the efficacy of the CT-P59 monoclonal antibody against t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 32b98e2c-9c8a-55d3-acad-6b7c096c57c8
DOI: 10.1101/2021.04.27.441707

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantDOI 10.1101/2021.04.27.441707Read

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantSemantic proximity Read

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.Semantic proximity Read

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesSemantic proximity Read

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccinationSemantic proximity Read

Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2Semantic proximity Read

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodiesSemantic proximity Read

Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.Semantic proximity Read

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals.Semantic proximity Read

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.Semantic proximity Read

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variantSemantic proximity Read

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesSemantic proximity Read

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read